Circulating tumor DNA in patients with stage 2/3 HR+HER2-negative breast cancer receiving neoadjuvant endocrine therapy in the I-SPY2 Endocr
Alkhafaji S, Magbanua MJM, van ‘t Veer L, et al. Oral presentation presented at ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.